What does HSP90 stand for?

today announced that preclinical results presented at the American Association for Cancer Research 101st Annual Meeting show that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 demonstrates synergy with standard of care therapies such as Avastin in non-small cell lung cancer models; penetrates efficiently into hypoxic regions of tumors; and inhibits both HIF-1a and JAK/STAT signaling, pathways that are critical to the survival and proliferation of certain cancer types.

Rubenstein will be presenting an overview of the Company's preclinical results related to its series of heat shock protein 90 (Hsp90) inhibitors, speak about the Company's forward drug development strategy and timeline, and present high-level fiscal results for 2009.

of Salt Lake City, said the FDA cleared its investigational new drug application to begin a Phase I study of MPC-3100, a fully synthetic, orally bioavailable, small-molecule inhibitor of Heat shock protein 90, for the treatment of cancer.

It also acted as an aryl hydrocarbon receptor an-tagonist by directly binding the receptor's molecular chaperone, heat shock protein 90.

IPI-504 (retaspimycin hydrochloride) is Infinity's lead anti-chaperone therapy targeting heat shock protein 90.

com following the respective presentations: SGI-1776: Synergistic Activity of Co-Treatment with PIM1 Kinase Inhibitor SGI-1776 and Histone Deacetylase Inhibitor Panobinostat or Heat Shock Protein 90 Inhibitor AUY922 against Human CML and Myeloproliferative Neoplasm (MPN) Cells Abstract 2651, Sunday Dec 6, 6:00 - 8:00 pm CT AXL: Targeting Axl Kinase in Hematological Malignancies Abstract 2758, Sunday Dec 6, 6:00 - 8:00 pm CT About SuperGen SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation.

has an extensive compound library that targets heat shock protein 90 (Hsp90), a cancer target.

com/research/b1a141/competitor_analysi) has announced the addition of the "Competitor Analysis: Heat shock protein 90 (Hsp90) Inhibitors" report to their offering.